July 6th, 2026
In recent years, researchers have noted that one variant of the BPIFB4 gene is associated with human longevity. This was discovered in the usual way, by noting that older populations tend to have a higher proportion of individuals carrying the variant than is the case for younger populations. In other words, individuals without the protective variant have an incrementally higher mortality rate. The longevity-associated variant of BPIFB4 appears to reduce cardiovascular dysfunction and mortality, and also reduces the chronic inflammatory signaling characteristic of aging. That slowed cardiovascular aging may or may not be entirely a consequence of the reduced inflammation; that remains to be determined.
Studies in mice have shown similar outcomes, and, interestingly, the BPIFB4 protein is robust enough to deliver orally and still produce benefits. Meanwhile, investigations of the underlying biochemistry of BPIFB4 and its role in the body continues, seeking a better understanding of how exactly it works.
Today's open access paper reports on new findings regarding the way in which BPIFB4 interacts with the immune system, which appears to be mediated via the activities of platelets. Platelets are cell fragments manufactured by megakaryocyte cells; they might be thought of as mini-cells that exhibit the surface features and some of the contents of their megakaryocyte progenitors. The primary purpose of platelets is to produce clotting when needed, but even when that is not happening, platelets are active participants in the complex dance of interactions between cells. Researchers suggest that effects hinge on the degree to which CD47 appears on platelet surface membranes, which offers a possible path to developing a drug to mimic BPIFB4 benefits.
